Melflufen is a modified version of melphalan. Multiple myeloma cells have enzymes that are overexpressed at very high levels. Melflufen is trapped at higher concentrations within diseased cells, so it is more targeted than melphalan. According to the company developing the drug, Oncopeptides AB in Sweden, melflufen has a 50-100x higher anti-tumor potency over melphalan. The new drug melflufen is now being tested with dexamethasone for patients with relapsed/refractory multiple myeloma. One of the study goals is to use the drug for patients who have become refractory to pomalidomide and/or daratumumab. Patients will be treated with melflufen on Day 1 and then dex on days 1, 8, 15 and 22 of a 28-day cycle. To find this clinical trial on SparkCures, click here: Melflufen and Dex Clinical Trial
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.